Recursion Pharmaceuticals
NASDAQ · RXRX·Salt Lake City, UT·Mid-cap·Phase 2
AI-driven drug discovery biotech using its Recursion OS platform combining wet-lab automation, large-scale phenomics, and ML. Pipeline of small-molecule programs in oncology and rare disease, including REC-994 (CCM), REC-2282 (NF2), REC-4881 (FAP), and REC-617 (CDK7).
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Recursion 4Q & FY 2025 Corporate Presentation | Corporate overview | February 26, 2026 | 39 |